The Filings Report

AbbVie

ABBVNYSECIK 1551152Healthcare / Drug Manufacturersfiscal year ends December58 quarters since 2012

Revenue, Q2 FY2026
$17.0B
+10.2% on Q2 FY2025
Net income
$3.6B
+285.2% on Q2 FY2025
Free cash flow
$3.1B
−36.2% on Q2 FY2025
Diluted EPS
$2.03
+290.4% on Q2 FY2025
Revenue, TTM
$64.4B
trailing four quarters
Net margin, TTM
9.8%
net income $6.3B
Free cash flow, TTM
$18.2B
$19.5B less $1.3B capex
Cash and equivalents
$6.6B
long-term debt —, Jun 30, 2026
Shares, 12-month change
+0.0%
1.77B shares, Jun 30, 2026
Buybacks, TTM
$1.5B
0.3% of market value
Dividends, TTM
$12.0B
2.3% of market value
Market value
$521.1B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 3, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, AbbVie reported revenue of $17.0B, +10.2% on Q2 FY2025, and net income of $3.6B (+285.2%). Operating margin was 37.9%. Free cash flow, operating cash flow less capital expenditures, was $3.1B ($3.4B less $322M). Diluted earnings per share were $2.03.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 3, 2026.

Revenue and net incomeRevenueNet income
−$5B$0$5B$10B$15B$20BQ3'22, Revenue: $14.8BQ3'22, Net income: $3.9BQ3'22Q4'22, Revenue: $15.1BQ4'22, Net income: $2.5BQ4'22Q1'23, Revenue: $12.2BQ1'23, Net income: $239MQ1'23Q2'23, Revenue: $13.9BQ2'23, Net income: $2.0BQ2'23Q3'23, Revenue: $13.9BQ3'23, Net income: $1.8BQ3'23Q4'23, Revenue: $14.3BQ4'23, Net income: $822MQ4'23Q1'24, Revenue: $12.3BQ1'24, Net income: $1.4BQ1'24Q2'24, Revenue: $14.5BQ2'24, Net income: $1.4BQ2'24Q3'24, Revenue: $14.5BQ3'24, Net income: $1.6BQ3'24Q4'24, Revenue: $15.1BQ4'24, Net income: −$22MQ4'24Q1'25, Revenue: $13.3BQ1'25, Net income: $1.3BQ1'25Q2'25, Revenue: $15.4BQ2'25, Net income: $938MQ2'25Q3'25, Revenue: $15.8BQ3'25, Net income: $186MQ3'25Q4'25, Revenue: $16.6BQ4'25, Net income: $1.8BQ4'25Q1'26, Revenue: $15.0BQ1'26, Net income: $695MQ1'26Q2'26, Revenue: $17.0BQ2'26, Net income: $3.6BQ2'26−$5B$0$5B$10B$15B$20BQ3'22, Revenue: $14.8BQ3'22, Net income: $3.9BQ4'22, Revenue: $15.1BQ4'22, Net income: $2.5BQ4'22Q1'23, Revenue: $12.2BQ1'23, Net income: $239MQ2'23, Revenue: $13.9BQ2'23, Net income: $2.0BQ2'23Q3'23, Revenue: $13.9BQ3'23, Net income: $1.8BQ4'23, Revenue: $14.3BQ4'23, Net income: $822MQ4'23Q1'24, Revenue: $12.3BQ1'24, Net income: $1.4BQ2'24, Revenue: $14.5BQ2'24, Net income: $1.4BQ2'24Q3'24, Revenue: $14.5BQ3'24, Net income: $1.6BQ4'24, Revenue: $15.1BQ4'24, Net income: −$22MQ4'24Q1'25, Revenue: $13.3BQ1'25, Net income: $1.3BQ2'25, Revenue: $15.4BQ2'25, Net income: $938MQ2'25Q3'25, Revenue: $15.8BQ3'25, Net income: $186MQ4'25, Revenue: $16.6BQ4'25, Net income: $1.8BQ4'25Q1'26, Revenue: $15.0BQ1'26, Net income: $695MQ2'26, Revenue: $17.0BQ2'26, Net income: $3.6BQ2'26

Net income losses drawn in red.

Free cash flow
$0$2B$4B$6B$8BQ3'22, Free cash flow: $7.4BQ3'22Q4'22, Free cash flow: $7.2BQ4'22Q1'23, Free cash flow: $4.0BQ1'23Q2'23, Free cash flow: $6.1BQ2'23Q3'23, Free cash flow: $7.4BQ3'23Q4'23, Free cash flow: $4.5BQ4'23Q1'24, Free cash flow: $3.8BQ1'24Q2'24, Free cash flow: $2.0BQ2'24Q3'24, Free cash flow: $5.2BQ3'24Q4'24, Free cash flow: $6.8BQ4'24Q1'25, Free cash flow: $1.4BQ1'25Q2'25, Free cash flow: $4.9BQ2'25Q3'25, Free cash flow: $6.6BQ3'25Q4'25, Free cash flow: $4.9BQ4'25Q1'26, Free cash flow: $3.6BQ1'26Q2'26, Free cash flow: $3.1BQ2'26$0$2B$4B$6B$8BQ3'22, Free cash flow: $7.4BQ4'22, Free cash flow: $7.2BQ4'22Q1'23, Free cash flow: $4.0BQ2'23, Free cash flow: $6.1BQ2'23Q3'23, Free cash flow: $7.4BQ4'23, Free cash flow: $4.5BQ4'23Q1'24, Free cash flow: $3.8BQ2'24, Free cash flow: $2.0BQ2'24Q3'24, Free cash flow: $5.2BQ4'24, Free cash flow: $6.8BQ4'24Q1'25, Free cash flow: $1.4BQ2'25, Free cash flow: $4.9BQ2'25Q3'25, Free cash flow: $6.6BQ4'25, Free cash flow: $4.9BQ4'25Q1'26, Free cash flow: $3.6BQ2'26, Free cash flow: $3.1BQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$20B$40B$60B$80BQ3'22, Cash and equivalents: $11.8BQ3'22Q4'22, Cash and equivalents: $9.2BQ4'22, Long-term debt: $63.1BQ4'22Q1'23, Cash and equivalents: $6.7BQ1'23Q2'23, Cash and equivalents: $8.8BQ2'23Q3'23, Cash and equivalents: $13.3BQ3'23Q4'23, Cash and equivalents: $12.8BQ4'23, Long-term debt: $59.2BQ4'23Q1'24, Cash and equivalents: $18.1BQ1'24Q2'24, Cash and equivalents: $13.1BQ2'24Q3'24, Cash and equivalents: $7.3BQ3'24Q4'24, Cash and equivalents: $5.5BQ4'24, Long-term debt: $66.8BQ4'24Q1'25, Cash and equivalents: $5.2BQ1'25Q2'25, Cash and equivalents: $6.5BQ2'25Q3'25, Cash and equivalents: $5.6BQ3'25Q4'25, Cash and equivalents: $5.2BQ4'25, Long-term debt: $64.5BQ4'25Q1'26, Cash and equivalents: $9.4BQ1'26Q2'26, Cash and equivalents: $6.6BQ2'26$0$20B$40B$60B$80BQ3'22, Cash and equivalents: $11.8BQ4'22, Cash and equivalents: $9.2BQ4'22, Long-term debt: $63.1BQ4'22Q1'23, Cash and equivalents: $6.7BQ2'23, Cash and equivalents: $8.8BQ2'23Q3'23, Cash and equivalents: $13.3BQ4'23, Cash and equivalents: $12.8BQ4'23, Long-term debt: $59.2BQ4'23Q1'24, Cash and equivalents: $18.1BQ2'24, Cash and equivalents: $13.1BQ2'24Q3'24, Cash and equivalents: $7.3BQ4'24, Cash and equivalents: $5.5BQ4'24, Long-term debt: $66.8BQ4'24Q1'25, Cash and equivalents: $5.2BQ2'25, Cash and equivalents: $6.5BQ2'25Q3'25, Cash and equivalents: $5.6BQ4'25, Cash and equivalents: $5.2BQ4'25, Long-term debt: $64.5BQ4'25Q1'26, Cash and equivalents: $9.4BQ2'26, Cash and equivalents: $6.6BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 3, 2026.

AbbVie income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 3, 2026Q1 FY2026ended Mar 31, 2026filed May 8, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025Q3 FY2024ended Sep 30, 2024filed Nov 4, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue16,99015,00216,61815,77615,42313,34315,10214,460+10.2%
Cost of revenue4,2914,2184,5525,3044,3464,0024,3964,212−1.3%
Gross profit——12,066———10,706——
Research and development—————————
Selling, general and administrative3,6323,5783,8953,5693,2533,2933,8554,205+11.7%
Operating income6,4323,9904,5441,9044,8943,733(1,490)3,831+31.4%
Other income (expense)(1,475)(2,306)(1,210)(503)(2,662)(1,445)(150)(1,159)+44.6%
Pretax income4,2781,0392,6687141,5541,661(2,269)2,084+175.3%
Income tax662342853526613372(2,246)520+8.0%
Net income3,6136951,8161869381,286(22)1,561+285.2%
Diluted EPS ($)2.030.391.020.100.520.72(0.02)0.88+290.4%
Diluted shares (millions)1,7711,774—1,7721,7711,772—1,772—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 3, 2026.

AbbVie balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 3, 2026Q1 FY2026ended Mar 31, 2026filed May 8, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025Q3 FY2024ended Sep 30, 2024filed Nov 4, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents6,5699,3915,2295,6296,4675,1755,5247,257+1.6%
Short-term investments——2842013128—
Total current assets33,66933,52929,06228,53929,26127,67525,58227,785+15.1%
Total assets135,115136,463133,960133,898137,182136,165135,161143,422−1.5%
Total current liabilities41,64242,10043,28939,39139,76736,40338,74943,062+4.7%
Long-term debt——64,503———66,841——
Total liabilities—————————
Stockholders’ equity(5,935)(6,656)(3,270)(2,642)(183)1,4203,3256,032−3143.2%
Shares outstanding (millions)1,7671,7671,7681,7671,7671,7661,7651,767—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 3, 2026.

AbbVie cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 3, 2026Q1 FY2026ended Mar 31, 2026filed May 8, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 9, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025Q3 FY2024ended Sep 30, 2024filed Nov 4, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow3,4363,8295,2187,0245,1531,6357,0485,447−33.3%
Capital expenditures322265329381269235291249+19.7%
Free cash flow (CFO − capex)3,1143,5644,8896,6434,8841,4006,7575,198−36.2%
Depreciation and amortization—————————
Share repurchases91,489341296135817−25.0%
Dividends paid3,0703,0862,9112,9112,9102,9252,7522,751+5.5%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 20, 2026.

Income statement

AbbVie income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed Feb 20, 2024FY2022ended Dec 31, 2022filed Feb 17, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Dec 31, 2020filed Feb 19, 2021FY2019ended Dec 31, 2019filed Feb 21, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 20, 2015FY2013ended Dec 31, 2013filed Feb 21, 2014FY2012ended Dec 31, 2012filed May 8, 2013FY2011ended Dec 31, 2011filed May 8, 2013
Revenue61,16056,33454,31858,05456,19745,80433,26632,75328,21625,63822,85919,96018,79018,38017,444
Cost of revenue18,20416,90420,41517,41417,44615,3877,4397,7187,0425,832—————
Gross profit———————————————
Research and development———————————————
Selling, general and administrative14,01014,75212,87215,26012,34911,2996,9427,3996,2955,8816,3877,7245,3524,9895,894
Operating income15,0759,13712,75718,11717,92411,36312,9836,3839,5459,3407,5373,4115,6645,8173,620
Other income (expense)(5,793)(3,240)(4,677)(2,448)(2,500)(5,614)(3,006)(18)(466)(188)(13)2719(2)
Pretax income6,5973,7166,25013,47712,9893,3988,4265,1977,7277,8846,6452,3695,3325,7253,668
Income tax2,364(570)1,3771,6321,440(1,224)544(490)2,4181,9311,5015951,204450235
Net income4,2264,2784,86311,83611,5424,6167,8825,6875,3095,9535,1441,774———
Diluted EPS ($)2.362.392.726.636.452.725.283.663.303.633.131.102.563.352.18
Diluted shares (millions)1,7731,7731,7731,7781,7771,6731,4841,5461,6031,6311,6371,6101,6041,5771,577

Balance sheet

AbbVie balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed Feb 20, 2024FY2022ended Dec 31, 2022filed Feb 17, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Dec 31, 2020filed Feb 19, 2021FY2019ended Dec 31, 2019filed Feb 21, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 20, 2015FY2013ended Dec 31, 2013filed Feb 21, 2014FY2012ended Dec 31, 2012filed May 8, 2013FY2011ended Dec 31, 2011filed May 8, 2013
Cash and equivalents5,2295,52412,8149,2019,7468,44939,9247,2899,3035,1008,3998,3489,5955,90127
Short-term investments2831228843007724861,3238263002,075—
Total current assets29,06225,58233,00228,46327,92824,17349,51916,94521,22316,18716,31416,08117,84815,354—
Total assets133,960135,161134,711138,805146,529150,56589,11559,35270,78666,09953,05027,51329,19827,008—
Total current liabilities43,28938,74937,84129,53835,19428,66115,58517,23916,6419,78110,89411,3936,8796,776—
Long-term debt64,50366,84159,24563,12875,96284,94867,233————————
Total liabilities———————————————
Stockholders’ equity(3,270)3,32510,36017,25415,40813,076(8,172)(8,446)5,0974,6363,9451,7424,492(350)—
Shares outstanding (millions)1,7681,7651,7661,7691,7691,7661,4791,4751,5881,5941,6111,5941,5891,584—

Cash flow statement

AbbVie cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed Feb 20, 2024FY2022ended Dec 31, 2022filed Feb 17, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Dec 31, 2020filed Feb 19, 2021FY2019ended Dec 31, 2019filed Feb 21, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 16, 2018FY2016ended Dec 31, 2016filed Feb 17, 2017FY2015ended Dec 31, 2015filed Feb 19, 2016FY2014ended Dec 31, 2014filed Feb 20, 2015FY2013ended Dec 31, 2013filed Feb 21, 2014FY2012ended Dec 31, 2012filed May 8, 2013FY2011ended Dec 31, 2011filed May 8, 2013
Operating cash flow19,03018,80622,83924,94322,77717,58813,32413,4279,960——————
Capital expenditures1,214974777695787798552638529479532612491333356
Free cash flow (CFO − capex)17,81617,83222,06224,24821,99016,79012,77212,7899,431——————
Depreciation and amortization———————————————
Share repurchases9801,7081,9721,48793497862912,0141,4106,0337,586665320——
Dividends paid11,65711,02510,53910,0439,2617,7166,3665,5804,1073,7173,2942,6612,555——

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$8M
1 sales by 1 insider; officers and directors $8M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$19M
6 sales by 3 insiders; officers and directors $19M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Aug 14, 2026Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERoption exercise32,710$79.02$3M107,140Aug 18, 2026
Aug 14, 2026Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERopen-market sale32,710$250.00$8M74,430Aug 18, 2026
May 8, 2026Falk Thomas JDirectoraward1,118$0.00—2,321May 12, 2026
May 8, 2026Waddell Frederick HDirectoraward1,118$0.00—30,076May 12, 2026
May 8, 2026Roberts Rebecca BDirectoraward1,118$0.00—14,846May 12, 2026
May 8, 2026Rapp Edward JDirectoraward1,118$0.00—45,964May 12, 2026
May 8, 2026Quaggin Susan EDirectoraward1,118$0.00—3,643May 12, 2026
May 8, 2026Meyer Melody BDirectoraward1,118$0.00—17,616May 12, 2026
May 8, 2026Hart Brett JDirectoraward1,118$0.00—20,590May 12, 2026
May 8, 2026Freyman Thomas CDirectoraward1,118$0.00—127,869May 12, 2026
May 8, 2026Davis Jennifer L.Directoraward1,118$0.00—3,643May 12, 2026
May 8, 2026Burnside William H.L.Directoraward1,118$0.00—28,076May 12, 2026
May 8, 2026Austin Roxanne SDirectoraward1,118$0.00—39,576May 12, 2026
Mar 4, 2026Purdue David RyanSVP, Controlleropen-market sale5,230$233.56$1M2,654Mar 6, 2026
Mar 2, 2026Siatis Perry CEVP, GC AND SECRETARYopen-market sale10b5-110,291$234.66$2M7,219Mar 3, 2026
Mar 2, 2026Siatis Perry CEVP, GC AND SECRETARYopen-market sale10b5-12,600$235.26$612K4,619Mar 3, 2026
Mar 2, 2026Siatis Perry CEVP, GC AND SECRETARYopen-market sale10b5-15,777$233.51$1M17,510Mar 3, 2026
Feb 27, 2026Purdue David RyanSVP, Controllertax withholding2,108$232.08$489K8,468Mar 11, 2026
Feb 27, 2026Crum Demetris DEVP, CHIEF HR OFFICERtax withholding1,594$232.08$370K7,914Mar 6, 2026
Feb 27, 2026Thakkar RoopalEVP, R&D and CSOtax withholding8,037$232.08$2M52,376Mar 3, 2026
Feb 27, 2026Michael Robert A.CHAIRMAN OF THE BOARD AND CEO, Directortax withholding36,523$232.08$8M178,737Mar 3, 2026
Feb 27, 2026Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERtax withholding23,812$232.08$6M83,171Mar 3, 2026
Feb 27, 2026Siatis Perry CEVP, GC AND SECRETARYtax withholding14,850$232.08$3M23,287Mar 3, 2026
Feb 27, 2026Saleki-Gerhardt AzitaEVP, CHIEF OPERATIONS OFFICERtax withholding16,309$232.08$4M197,794Mar 3, 2026
Feb 27, 2026Reents Scott TEVP, CHIEF FINANCIAL OFFICERtax withholding21,638$232.08$5M38,777Mar 3, 2026

Full insider history for AbbVie, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
AbbVie Inc., CIK 1551152 on EDGAR
Extract generated
August 27, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: not filed
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt
Total liabilities: not filed
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: not filed
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated August 27, 2026.

JSON file
/data/financials/ABBV.json